United Therapeutics Corporation (NASDAQ:UTHR) – Leerink Swann lowered their FY2018 earnings per share (EPS) estimates for United Therapeutics Corporation in a research report issued on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $10.73 per share for the year, down from their previous forecast of $11.57. Leerink Swann also issued estimates for United Therapeutics Corporation’s FY2019 earnings at $6.79 EPS.

Several other analysts have also recently weighed in on UTHR. HC Wainwright reissued a “hold” rating and issued a $95.00 price target on shares of United Therapeutics Corporation in a research note on Thursday. Cowen and Company restated a “hold” rating and issued a $129.00 price objective on shares of United Therapeutics Corporation in a report on Friday. TheStreet lowered shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Jefferies Group LLC restated a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a report on Friday, July 14th. Finally, ValuEngine upgraded shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $132.82.

ILLEGAL ACTIVITY WARNING: “FY2018 EPS Estimates for United Therapeutics Corporation (UTHR) Decreased by Leerink Swann” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/27/fy2018-eps-estimates-for-united-therapeutics-corporation-uthr-decreased-by-leerink-swann.html.

Shares of United Therapeutics Corporation (UTHR) traded up 0.80% during mid-day trading on Friday, reaching $120.05. 462,617 shares of the company’s stock traded hands. The stock has a market capitalization of $5.22 billion, a PE ratio of 13.92 and a beta of 1.49. The company’s 50-day moving average price is $121.15 and its 200-day moving average price is $125.71. United Therapeutics Corporation has a 12-month low of $112.01 and a 12-month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.83%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $4.23 earnings per share.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,263 shares of the firm’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $120.38, for a total transaction of $152,039.94. Following the transaction, the chief executive officer now directly owns 1,403 shares of the company’s stock, valued at approximately $168,893.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total transaction of $77,998.40. Following the transaction, the director now directly owns 3,295 shares in the company, valued at $443,111.60. The disclosure for this sale can be found here. Insiders sold a total of 18,368 shares of company stock worth $2,295,419 over the last ninety days. Insiders own 7.80% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Eagle Global Advisors LLC purchased a new position in United Therapeutics Corporation during the 2nd quarter worth $206,000. TLP Group LLC acquired a new stake in shares of United Therapeutics Corporation in the 2nd quarter worth $246,000. HPM Partners LLC lifted its stake in shares of United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 15 shares during the period. Fort L.P. lifted its stake in shares of United Therapeutics Corporation by 5.2% in the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after acquiring an additional 99 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in shares of United Therapeutics Corporation by 4.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 95 shares during the period.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.